Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0CRAKG
ADC Name
MMAE.VC.SA.617
Synonyms
MMAE VC SA 617; MMAE-VC-SA-617
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Prostate cancer [ICD11:2C82]
Investigative
Antibody Name
Undisclosed
Antigen Name
Glutamate carboxypeptidase 2 (FOLH1)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 87.5
%
LNCaP cells
Prostate carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 87.50% (Day 30) Positive PSMA expression (PSMA +++/++)
Method Description
In order to specify the pharmacological properties of MMAE.VC.SA.617 we inoculated LNCaP cells into NOD/SCID mice to generate a xenograft model. In vivo therapeutic efficacy studies were conducted with MMAE.VC.SA.617, namely 1.0 mg/kg (corresponding to 0.49 mg MMAE).
In Vivo Model LNCaP CDX model
In Vitro Model Prostate carcinoma LNCaP cells CVCL_0395
References
Ref 1 Old Drug, New Delivery Strategy: MMAE Repackaged. Int J Mol Sci. 2023 May 10;24(10):8543. doi: 10.3390/ijms24108543.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.